---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-000270"
form_type: "8-K"
ticker: "GNLX"
cik: "0001231457"
company_name: "GENELUX Corp"
filed_at: "2026-01-05T23:59:59+00:00"
generated_at: "2026-05-16T11:38:21.360425+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Genelux reports 33% ORR in SCLC and 60% DCR in NSCLC with systemic Olvi-Vec

## Summary
- SCLC Phase 1b/2: 33% ORR (3/9 PRs), 67% DCR; highest dose cohort 67% ORR (2/3) with tumor shrinkage ~55% and ~85%.
- NSCLC Phase 2 VIRO-25: 60% DCR (3/5 patients); tumor size changes -18.9% and -22.7% in two of three DCR patients.
- Durability signals: two SCLC PR patients had PFS of 12.1 mo (1 prior line) and 7.7 mo (4 prior lines).
- Topline Phase 3 ovarian cancer data expected H2 2026; additional lung cancer interim readouts throughout 2026.

## SEC filing metadata
- accession: 0001493152-26-000270
- form_type: 8-K
- ticker: GNLX
- cik: 0001231457
- company_name: GENELUX Corp
- filed_at: 2026-01-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1231457/000149315226000270/0001493152-26-000270-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1231457/000149315226000270/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-000270
- JSON: https://secwatch.observer/filing/0001493152-26-000270.json
- Plain text: https://secwatch.observer/filing/0001493152-26-000270.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.